
A prospective study analyzed 3,402 atrial fibrillation (AF) patients from the COOL AF Thailand registry (2014–2017) to assess the net clinical benefit (NCB) of oral anticoagulants (OACs) according to CHA2DS2-VASc score. The study revealed that AF patients with a CHA2DS2-VASc score of 3 or more, whether on warfarin or direct oral anticoagulants (DOACs), demonstrated a positive NCB. Notably, DOACs exhibited a more favorable NCB compared to warfarin, and females showed a higher NCB than males, emphasizing gender and OAC-type variations in treatment outcomes.
Like
Save
Share